GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (XTER:ZEG) » Definitions » Research & Development

AstraZeneca (XTER:ZEG) Research & Development : €10,979 Mil (TTM As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. AstraZeneca's Research & Development for the three months ended in Sep. 2024 was €2,807 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was €10,979 Mil.


AstraZeneca Research & Development Historical Data

The historical data trend for AstraZeneca's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Research & Development Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,453.10 4,924.60 8,616.36 9,215.33 10,027.40

AstraZeneca Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,421.21 2,817.94 2,560.36 2,794.43 2,806.62

AstraZeneca Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €10,979 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca  (XTER:ZEG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


AstraZeneca Research & Development Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines